Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 3 | 2025 | 28 | 1.780 |
Why?
|
| Ovarian Neoplasms | 10 | 2024 | 418 | 1.540 |
Why?
|
| Adenocarcinoma | 3 | 2025 | 998 | 1.460 |
Why?
|
| Lung Neoplasms | 2 | 2025 | 1604 | 0.960 |
Why?
|
| Synaptophysin | 1 | 2024 | 17 | 0.960 |
Why?
|
| Carcinoma | 3 | 2024 | 285 | 0.950 |
Why?
|
| Juxtaglomerular Apparatus | 1 | 2024 | 7 | 0.950 |
Why?
|
| Glomus Tumor | 1 | 2024 | 13 | 0.950 |
Why?
|
| Carcinoid Tumor | 1 | 2024 | 25 | 0.940 |
Why?
|
| Fallopian Tube Neoplasms | 4 | 2024 | 14 | 0.810 |
Why?
|
| Cystadenocarcinoma, Serous | 7 | 2024 | 53 | 0.810 |
Why?
|
| Angiofibroma | 1 | 2021 | 5 | 0.750 |
Why?
|
| Carcinoma, Papillary | 1 | 2022 | 77 | 0.750 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2021 | 14 | 0.750 |
Why?
|
| Gout | 1 | 2024 | 148 | 0.730 |
Why?
|
| Adnexal Diseases | 1 | 2020 | 23 | 0.700 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2022 | 199 | 0.700 |
Why?
|
| Kidney Neoplasms | 1 | 2024 | 431 | 0.690 |
Why?
|
| Pleural Effusion | 1 | 2020 | 101 | 0.670 |
Why?
|
| Carcinoma in Situ | 4 | 2024 | 71 | 0.660 |
Why?
|
| Foreign-Body Reaction | 1 | 2019 | 15 | 0.660 |
Why?
|
| Aspergillosis | 1 | 2019 | 43 | 0.660 |
Why?
|
| Pneumonia, Aspiration | 1 | 2019 | 18 | 0.660 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2022 | 557 | 0.660 |
Why?
|
| Paramyxoviridae Infections | 1 | 2019 | 47 | 0.650 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2019 | 151 | 0.650 |
Why?
|
| Adenoma | 1 | 2020 | 131 | 0.640 |
Why?
|
| Airway Obstruction | 1 | 2021 | 166 | 0.640 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 79 | 0.610 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 1 | 2018 | 2 | 0.600 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 188 | 0.600 |
Why?
|
| Prostatic Neoplasms | 2 | 2025 | 1549 | 0.470 |
Why?
|
| Precancerous Conditions | 2 | 2019 | 283 | 0.350 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1894 | 0.320 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2024 | 724 | 0.290 |
Why?
|
| Humans | 22 | 2025 | 124822 | 0.280 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 1319 | 0.280 |
Why?
|
| Peritoneal Neoplasms | 1 | 2007 | 29 | 0.270 |
Why?
|
| Aged | 6 | 2025 | 19697 | 0.240 |
Why?
|
| DNA, Neoplasm | 2 | 2019 | 303 | 0.240 |
Why?
|
| Ovary | 1 | 2007 | 379 | 0.230 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2024 | 2 | 0.230 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2024 | 116 | 0.230 |
Why?
|
| Pancreatic Diseases | 1 | 2024 | 39 | 0.220 |
Why?
|
| Middle Aged | 8 | 2025 | 26730 | 0.220 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1473 | 0.220 |
Why?
|
| Pancreas | 1 | 2024 | 217 | 0.210 |
Why?
|
| Genital Neoplasms, Female | 1 | 2003 | 47 | 0.210 |
Why?
|
| Uroplakin II | 1 | 2022 | 1 | 0.200 |
Why?
|
| Keratins | 1 | 2022 | 55 | 0.200 |
Why?
|
| Urothelium | 1 | 2022 | 60 | 0.190 |
Why?
|
| Cadherins | 1 | 2022 | 165 | 0.180 |
Why?
|
| Female | 14 | 2025 | 66580 | 0.180 |
Why?
|
| Respiratory System | 1 | 2021 | 94 | 0.180 |
Why?
|
| Male | 6 | 2025 | 61314 | 0.170 |
Why?
|
| Dextrans | 1 | 2019 | 45 | 0.170 |
Why?
|
| Rectum | 1 | 2019 | 99 | 0.160 |
Why?
|
| Iatrogenic Disease | 1 | 2019 | 133 | 0.160 |
Why?
|
| Hyaluronic Acid | 1 | 2019 | 95 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 688 | 0.150 |
Why?
|
| Hemangiosarcoma | 1 | 2018 | 39 | 0.150 |
Why?
|
| Hematuria | 1 | 2018 | 54 | 0.150 |
Why?
|
| Taxoids | 1 | 2018 | 67 | 0.140 |
Why?
|
| Deoxycytidine | 1 | 2018 | 77 | 0.140 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2018 | 78 | 0.140 |
Why?
|
| Bilirubin | 1 | 2018 | 123 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 670 | 0.140 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 332 | 0.120 |
Why?
|
| Evolution, Molecular | 1 | 2019 | 674 | 0.120 |
Why?
|
| Abdominal Pain | 1 | 2018 | 309 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 780 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 2004 | 18 | 0.110 |
Why?
|
| Fallopian Tubes | 2 | 2024 | 73 | 0.100 |
Why?
|
| Adult | 3 | 2024 | 29484 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2025 | 2513 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1135 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1237 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2010 | 320 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2007 | 3288 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2007 | 183 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3589 | 0.070 |
Why?
|
| Cystadenoma, Serous | 1 | 2004 | 6 | 0.060 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 45 | 0.060 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 114 | 0.060 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 69 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 207 | 0.050 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2003 | 4 | 0.050 |
Why?
|
| Genes, ras | 1 | 2003 | 99 | 0.050 |
Why?
|
| ROC Curve | 1 | 2003 | 567 | 0.050 |
Why?
|
| Mutation | 4 | 2019 | 5815 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 791 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 551 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 1291 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 550 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2019 | 125 | 0.040 |
Why?
|
| DNA | 1 | 2024 | 1604 | 0.040 |
Why?
|
| Cystectomy | 1 | 2018 | 160 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2018 | 356 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2018 | 245 | 0.030 |
Why?
|
| Phylogeny | 1 | 2019 | 697 | 0.030 |
Why?
|
| Transcriptome | 1 | 2022 | 940 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2019 | 2307 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2019 | 333 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2004 | 170 | 0.030 |
Why?
|
| Risk Factors | 1 | 2007 | 10275 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 2052 | 0.030 |
Why?
|
| Genomics | 1 | 2019 | 1491 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2092 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 4615 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 1228 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 2036 | 0.020 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2004 | 10 | 0.010 |
Why?
|
| Carboplatin | 1 | 2004 | 77 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 125 | 0.010 |
Why?
|
| Clone Cells | 1 | 2004 | 168 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2004 | 79 | 0.010 |
Why?
|
| ras Proteins | 1 | 2004 | 137 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 237 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2004 | 158 | 0.010 |
Why?
|
| Codon | 1 | 2003 | 97 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2004 | 1068 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 782 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 1110 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1499 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1691 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 721 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 1792 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 1668 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 5156 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 6522 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2010 | 16296 | 0.010 |
Why?
|